Page 79 - MemoriaEHD-Eng

www.ciberehd.org

Most relevant • raMírez C, gregori J, Buti M, taBerNero D, CaMós s, CasiLLas r. A comparative study of ul-
tra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies
scientific
using hepatitis B virus infection as a model.Antiviral Res. 2013 May;98(2):273-83.
articles
• CuBero M, gregori J, esteBaN Ji, garCía-CehiC D, Bes M, peraLes C. Identification of host
and viral factors involved in a dissimilar resolution of a hepatitis C virus infection.

Liver Int. 2013 Oct 17;.

• gregori J, esteBaN Ji, CuBero M, garCía-CehiC D, peraLes C, CasiLLas r. Ultra-deep pyro-
sequencing (UDPS) data treatment to study amplicon HCV minor variants.PLoS One.

2013;8(12):e83361.

• sapisoChiN g, CasteLLs L, Dopazo C, BiLBao i, MiNguez B, Lázaro JL. Single HCC in cirrhotic

patients: liver resection or liver transplantation? Long-term outcome according to an
intention-to-treat basis.Ann Surg Oncol. 2013 Apr;20(4):1194-202.

• MarCo a, esteBaN Ji, soLé C, Da siLva a, ortiz J, roget M. Hepatitis C virus reinfection

among prisoners with sustained virological response after treatment for chronic he-
patitis C.J Hepatol. 2013 Jul;59(1):45-51.

PROJECTS
Highlights
• Quasispecies study of HCV and HBV and genomic polymorphisms associated with antiviral

resistance using ultra-deep pyrosequencing. Centro para el Desarrollo Tecnológico Industrial
(CDTI). MINECO. Ref. IDI-20110115. 2010-2013. JI. Esteban.

• Expansion/restauration of functional CD4 NS3-specific autologous cells to prevent VHC
post-transplant hepatic recurrence: Protocol optimization for clinical use. FIS. PI10/01505.

2011-2014. JI. Esteban.
•
HBV quasispecies complexity on X, precore and core regions: Association with severity of í
infection. FIS. PI12/01893. 2013-2015. F. Rodríguez-Frías.

• Prospective study to analyze the role of gut microbiota with fast evolution of hepatic
transplant. Proyecto interno VHIR-HUVH. 2013-2015. I. Bilbao.
àí

• Network 2009 SGR 383. Unitat de recerca en Malalties hepatobiliars. AGAUR. Generalitat
de Catalunya. 2010-2014. J. Genesc.

• Anti-HBc antibody prevalence in blood donors from high risk HBV geographic areas. Proyecto
interno VHIR-HUVH PR(BS)128/2013. M. Piron.

• Performance evaluation Elecsys HTLV I/II CIM RD001837/A13P004”. VHIR-HUVH

PR(BS)324/2013. S. Sauleda.
• Prevalence of HEV markers (anti-IgG/IgM and HEV RNA) in Catalonian blood donors. VHIR-

HUVH PR(BS)100/2013. S. Sauleda.
• Pilot study Elecsys CHAGAS on Elecsys study. VHIR-HUVH PR(BS)325/2013. M. Piron.

• Association of IL-28B polimorphism rs12979860 with ocult HBV infection. VHIR-HUVH

PR(BS)95/2013. 2013. M. Bes.
• Analysis of the role of suppressor mieloide cells in HCV infection. VHIR-HUVH PR(IR)297/2013.

2013. J. Barquinero. 13
• Determination of specificity and sensitivity of ELISA kits for the screening of blood against
20
T
infectious diseases. Cession of serum/plasma samples from blood donors for validation of OR
ELISA kits. VHIR-HUVH PR(BS)46/2013. 2013. S. Sauleda.
P
RE
PATENTS ÑL
óA
• Appl.number: EP13382278. Primers and methods for detecting Human Hepatitis C
NU
Virus (HCV) variants in an isolated sample. Country of priority: ESPAA. Priority N
A
data: 05Julio2013. Entity priority: VHIR, CIBEREHD, ROCHE. Extension countries: D /
EU. NATIONAL HCV SPANISH DATA BASE. HepatiC.
H
E
CLINICAL TRIALS ER
IB
EudraCT: 2010-024247-32. Oscar Len / EudraCT: 2013-001191-38. Ramn Charco
C

/ EudraCT: 2013-002802-30. Mara Buti / Exp: JIE-VHC-2012-01. Lluis Castells / 79
EPA(AG)42/2012(3426). Llus Castells / EudraCT: 2012-003463-22. J.I.Esteban.